SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lisa Y. Lenertz, Cory J. Baughman, Noelle V. Waldschmidt, Roman Thaler, Andre J. van Wijnen, Control of bone development by P2X and P2Y receptors expressed in mesenchymal and hematopoietic cells., Gene, 2015,

    CrossRef

  2. 2
    Isabel R. Orriss, The role of purinergic signalling in the musculoskeletal system, Autonomic Neuroscience, 2015,

    CrossRef

  3. 3
    Ning Wang, Alison Gartland, Targeting P2 receptors—current progress in treating musculoskeletal diseases, Current Opinion in Pharmacology, 2014, 16, 122

    CrossRef

  4. 4
    Alison Gartland, Purinergic ADP receptors: from block buster blood drugs to bone-disease busters, IBMS BoneKEy, 2013, 10,

    CrossRef

  5. 5
    Geoffrey Burnstock, Timothy R. Arnett, Isabel R. Orriss, Purinergic signalling in the musculoskeletal system, Purinergic Signalling, 2013, 9, 4, 541

    CrossRef

  6. 6
    Susanne Syberg, Andrea Brandao-Burch, Jessal J Patel, Mark Hajjawi, Timothy R Arnett, Peter Schwarz, Niklas R Jorgensen, Isabel R Orriss, Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo, Journal of Bone and Mineral Research, 2012, 27, 11
  7. 7
    P2RY12 and its role in osteoclast activity and bone remodeling, BoneKEy Reports, 2012, 1,

    CrossRef

  8. 8
    Therapeutic doses of clopidogrel increase fracture risk, BoneKEy Reports, 2012, 1,

    CrossRef